FDA Approves Donidalorsen, a Revolutionary RNA-Targeted Therapy for Hereditary Angioedema

The FDA has granted approval to donidalorsen (Dawnzera; Ionis Pharmaceuticals Inc.), marking a significant advancement in the treatment of hereditary angioedema (HAE). This new therapy is the first and only RNA-targeted treatment for HAE and is approved for the prophylactic prevention of attacks in adults and pediatric patients aged 12 and older. Administered via a self-injectable subcutaneous autoinjector, donidalorsen offers a new, convenient, and highly effective option for patients.

How the Treatment Works

HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling. These attacks are triggered by an overproduction of inflammatory mediators, which are activated by the protein plasma prekallikrein (PKK). Donidalorsen’s innovative mechanism of action is designed to directly target the RNA that codes for PKK, preventing the protein’s production. By stopping the inflammatory cascade at its source, the therapy is able to prevent HAE attacks before they occur.

Supporting Clinical Evidence

The FDA’s decision was based on the impressive results from the global OASIS-HAE study, a phase 3 clinical trial. The study successfully met its primary endpoint, demonstrating that donidalorsen significantly reduced the monthly HAE attack rate. When administered once every 4 weeks, the therapy achieved an 81% reduction in attacks compared to a placebo. This reduction was even more pronounced, reaching 87%, when measured from the second dose onward. Additionally, the study highlighted the therapy’s ability to reduce the severity of attacks, showing a nearly 90% reduction in moderate-to-severe HAE episodes.

Convenience and Long-Lasting Efficacy

The approval of donidalorsen is a major milestone for patients living with HAE, who often struggle with frequent and debilitating attacks. The convenience of a self-administered autoinjector, combined with a long dosing interval of once every four weeks, is expected to greatly improve the quality of life for many patients. As stated by Brett P. Monia, PhD, CEO of Ionis, “DAWNZERA will be the prophylactic treatment of choice for many people living with HAE.” This new therapy represents a promising future for managing and preventing HAE attacks.